Ellis J Neufeld

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1481685/publications.pdf

Version: 2024-02-01

290 papers	12,174 citations	20817 60 h-index	32842 100 g-index
293 all docs	293 docs citations	293 times ranked	10521 citing authors

#	Article	IF	Citations
1	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. British Journal of Haematology, 2022, 196, 380-389.	2.5	4
2	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	2.2	17
3	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121, 1400-1408.	3.4	14
4	Limited sampling strategies for accurate determination of extended halfâ€life factor VIII pharmacokinetics in severe haemophilia A patients. Haemophilia, 2021, 27, 408-416.	2.1	5
5	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood, 2021, 138, 1677-1690.	1.4	20
6	Pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2021, 68, e29148.	1.5	10
7	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
8	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open, 2021, 11, e044885.	1.9	2
9	Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. Blood, 2021, 138, 1039-1039.	1.4	0
10	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	27.0	177
11	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	1.4	7
12	Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products. Blood, 2020, 136, 17-18.	1.4	0
13	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	2.3	18
14	Regional variation and cost implications of prescribed extended halfâ€life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	2.1	38
15	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	4.1	37
16	Bioengineering hemophilia Aâ€“specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Advances, 2019, 3, 4166-4176.	5.2	15
17	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	46
18	Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study. Blood, 2019, 134, 903-903.	1.4	2

#	Article	IF	Citations
19	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	1.4	0
20	A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children. Blood, 2019, 134, 2369-2369.	1.4	7
21	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome. Blood, 2019, 134, 1114-1114.	1.4	1
22	Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics, 2018, 21, 762-769.	2.1	10
23	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
24	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	1.4	121
25	Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 1216-1222.	2.0	23
26	Immunogenicity, efficacy and safety of Nuwiq^{Â®} (humanâ€rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia Aâ€"Interim results from the NuProtect Study. Haemophilia, 2018, 24, 211-220.	2.1	26
27	Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 607-614.	2.3	13
28	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
29	Recombinant activated factor <scp>VII</scp> in approved indications: Update on safety. Haemophilia, 2018, 24, e275-e277.	2.1	7
30	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	1.4	11
31	Risk of post-procedural bleeding in children on intravenous fish oil. American Journal of Surgery, 2017, 214, 733-737.	1.8	16
32	Recombinant porcine factor <scp>VIII</scp> for highâ€risk surgery in paediatric congenital haemophilia A with highâ€titre inhibitor. Haemophilia, 2017, 23, e93-e98.	2.1	17
33	Clinical outcomes in a cohort of patients with heparinâ€induced thrombocytopenia. American Journal of Hematology, 2017, 92, 730-738.	4.1	49
34	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	4.1	10
35	Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices. Haemophilia, 2017, 23, 821-831.	2.1	11
36	Increasing observation rates in lowâ€risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP^{Â®}). Pediatric Blood and Cancer, 2017, 64, e26303.	1.5	14

#	Article	IF	Citations
37	Ringed sideroblasts in Î²â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26324.	1.5	4
38	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). Blood, 2017, 130, 752-752.	1.4	2
39	A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 149-157.	0.9	8
40	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatric Blood and Cancer, 2016, 63, 1822-1828.	1.5	8
41	Unrelated Donor Marrow (BMT) or Cord Blood Transplantation (UCBT) for Thalassemia Major after Reduced Intensity Conditioning (URTH Trial Extension). Biology of Blood and Marrow Transplantation, 2016, 22, S356.	2.0	0
42	Refractory autoimmune disease: an overview of when first-line therapy is not enough. Seminars in Hematology, 2016, 53, S35-S38.	3.4	1
43	Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD). Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1006-1008.	3.8	7
44	Recognizing the need for personalization of haemophilia patientâ€reported outcomes in the prophylaxis era. Haemophilia, 2016, 22, 825-832.	2.1	36
45	Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence:HEMO-Milestones Toolin a Comprehensive Hemophilia Clinic Setting. Pediatric Blood and Cancer, 2016, 63, 499-503.	1.5	6
46	Hemophilia Joint Health Score Poorly Predicts the Need for Musculoskeletal Referrals in Routine Clinical Practice. Blood, 2016, 128, 3784-3784.	1.4	1
47	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 249-249.	1.4	7
48	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	1.4	0
49	Patient Reported Outcomes to Assess Quality of Hemophilia Care in North India - Results of a Global Partnership. Blood, 2016, 128, 3587-3587.	1.4	0
50	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 4752-4752.	1.4	0
51	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	1.4	1
52	Skin Testing, Graded Challenge and Desensitization to Von Willebrand Factor (vWF) Products in Type III Von Willebrand Disease (VWD). Journal of Allergy and Clinical Immunology, 2015, 135, AB121.	2.9	1
53	Erythrocyte pyruvate kinase deficiency: 2015 status report. American Journal of Hematology, 2015, 90, 825-830.	4.1	140
54	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood, 2015, 126, 873-879.	1.4	124

#	Article	IF	Citations
55	Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). Pediatric Blood and Cancer, 2015, 62, 2223-2225.	1.5	18
56	Transition considerations for extended halfâ€life factor products. Haemophilia, 2015, 21, 285-288.	2.1	17
57	Author's response: â€˜Transition considerations for extended half-life factor productsâ€™. Haemophilia, 2015, 21, e454-e455.	2.1	2
58	Guidelines for the Standard Monitoring of Patients With Thalassemia. Journal of Pediatric Hematology/Oncology, 2015, 37, e162-e169.	0.6	65
59	Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatric Blood and Cancer, 2015, 62, 214-218.	1.5	31
60	Safety update on the use of recombinant activated factor VII in approved indications. Blood Reviews, 2015, 29, S34-S41.	5.7	50
61	Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magnetic Resonance Imaging, 2015, 33, 761-767.	1.8	54
62	CSF 5-Methyltetrahydrofolate Serial Monitoring to Guide Treatment of Congenital Folate Malabsorption Due to Proton-Coupled Folate Transporter (PCFT) Deficiency. JIMD Reports, 2015, 24, 91-96.	1.5	24
63	Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centreâ€based pharmacy hit the mark?. Haemophilia, 2015, 21, 190-195.	2.1	2
64	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	2.5	22
65	Pediatric Heparin-Induced Thrombocytopenia: Prevalence, Thrombotic Risk, and Application of the 4Ts Scoring System. Journal of Pediatrics, 2015, 166, 144-150.e1.	1.8	47
66	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	1.4	6
67	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136.	1.4	1
68	Rituximab for treatment of inhibitors in haemophilia A. Thrombosis and Haemostasis, 2014, 112, 445-458.	3.4	43
69	Transfusion complications in thalassemia patients: a report from the <scp>C</scp>enters for <scp>D</scp>isease <scp>C</scp>ontrol and <scp>P</scp>revention (CME). Transfusion, 2014, 54, 972-981.	1.6	97
70	Validation and reliability of a diseaseâ€specific quality of life measure (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (<scp>T</scp>r Haematology, 2014, 164, 431-437.	2.5	36
71	MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients. American Journal of Hematology, 2014, 89, 684-688.	4.1	19
72	Safety of recombinant activated factor VII (<scp>rFVII</scp>a) in patients with congenital haemophilia with inhibitors: overall <scp>rFVII</scp>a exposure and intervals following high (>240ÂÎ¼gÂkg^{â^'1}) <scp>rFVII</scp>a doses across clinical trials and registries. Haemophilia, 2014, 20, e23-31.	2.1	14

#	Article	IF	Citations
73	R2 and R2* are equally effective in evaluating chronic response to iron chelation. American Journal of Hematology, 2014, 89, 505-508.	4.1	32
74	Human T-cell lymphotropic virus type 1 infection among U.S. Thalassemia patients. Retrovirology, 2014, 11, .	2.0	2
75	The use of erythropoietinâ€stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. European Journal of Haematology, 2014, 93, 161-164.	2.2	9
76	Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia. Quality of Life Research, 2014, 23, 2277-2288.	3.1	49
77	Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). Value in Health, 2014, 17, 744-748.	0.3	20
78	Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. Blood, 2014, 124, 2818-2818.	1.4	1
79	Unmet Needs in Diagnosis and Treatment of Glanzmannâ€™s Thrombasthenia (GT): Perceptions of US Hematologists and Nurses. Blood, 2014, 124, 2179-2179.	1.4	0
80	Novel dominant Î²â€thalassemia: Hb Bostonâ€Kuwait [Codon 139/140(+T)]. Pediatric Blood and Cancer, 2013, 60, E131-4.	1.5	10
81	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38.	3.3	47
82	Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. American Journal of Hematology, 2013, 88, 771-773.	4.1	25
83	Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403.	2.5	7
84	To Treat or Not To Treatâ€"From Guidelines to Individualized Patient Management. Seminars in Hematology, 2013, 50, S12-S17.	3.4	6
85	Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion. Stem Cells, 2013, 31, 1287-1297.	3.2	92
86	Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplantation, 2013, 48, 146-147.	2.4	27
87	Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE). Haemophilia, 2013, 19, 524-532.	2.1	8
88	Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. AIDS Research and Human Retroviruses, 2013, 29, 1006-1009.	1.1	5
89	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood, 2013, 121, 4457-4462.	1.4	87
90	Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004â€"2008). Pediatric Blood and Cancer, 2013, 60, 1178-1183.	1.5	9

#	Article	IF	Citations
91	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica, 2013, 98, 1359-1367.	3.5	40
92	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). Blood, 2013, 122, 543-543.	1.4	9
93	MRI-Guided Iron Assessment and Oral Chelator Use Improve Iron Status In Thalassemia Major Patients: a Six-Year Single Center Retrospective Cohort Study. Blood, 2013, 122, 563-563.	1.4	1
94	Liver MRI Is Better Than Biopsy For Assessing Total Body Iron Balance: Validation By Simulation. Blood, 2013, 122, 958-958.	1.4	8
95	Coagulopathy and Vascular Malformations. , 2013, , 637-644.		1
96	Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia. Blood, 2013, 122, 2180-2180.	1.4	0
97	Association Of Platelet Function Markers, Independent Of Platelet Count, With Bleeding Score In Patients With Immune Thrombocytopenia. Blood, 2013, 122, 3534-3534.	1.4	0
98	R2 and R2* Are Equally Effective In Evaluating Chronic Response To Iron Chelation. Blood, 2013, 122, 3437-3437.	1.4	0
99	Tracking the impact of the National Institutes of Health Clinical and Translational Science Awards on child health research: developing and evaluating a measurement strategy. Pediatric Research, 2012, 71, 619-624.	2.3	5
100	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 2012, 119, 2746-2753.	1.4	78
101	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	1.4	48
102	Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood, 2012, 120, 748-760.	1.4	107
103	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, 2012, 119, 5989-5995.	1.4	284
104	Inadequate Dietary Intake in Patients with Thalassemia. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 980-990.	0.8	39
105	Beliefs about chelation among thalassemia patients. Health and Quality of Life Outcomes, 2012, 10, 148.	2.4	28
106	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value in Health, 2012, 15, 916-925.	0.3	47
107	Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatric Blood and Cancer, 2012, 58, 216-220.	1.5	17
108	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood and Cancer, 2012, 58, 221-225.	1.5	29

#	Article	IF	Citations
109	Thirtyâ€day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: Risk factors and hospital variation. Pediatric Blood and Cancer, 2012, 58, 61-65.	1.5	47
110	Does iron overload really matter in stem cell transplantation?. American Journal of Hematology, 2012, 87, 569-572.	4.1	65
111	Trends in anti-D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects. American Journal of Hematology, 2012, 87, 315-317.	4.1	15
112	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	1.4	2
113	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. Blood, 2012, 120, 2122-2122.	1.4	1
114	Treatments and Outcomes of Immune Cytopenias Following Pediatric Solid Organ Transplant. Blood, 2012, 120, 5154-5154.	1.4	0
115	High Diagnostic Utility of Second-Day Factor VIII Levels to Assess Pediatric Hemophilia A Pharmacokinetics. Blood, 2012, 120, 3368-3368.	1.4	0
116	Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 852-860.	2.0	98
117	Risks Factors And Mortality Associated With Doppler-Defined-Pulmonary Hypertension In Thalassemia Major: A Report From The Thalassemia Clinical Research Network Longitudinal Cohort Study. , 2011, , .		1
118	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood, 2011, 118, 3794-3802.	1.4	55
119	A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica, 2011, 96, 521-525.	3.5	37
120	Renal dysfunction in patients with thalassaemia. British Journal of Haematology, 2011, 153, 111-117.	2.5	81
121	The frequency and management of asparaginaseâ€related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€Farber Cancer Institute consortium protocols. British Journal of Haematology, 2011, 152, 452-459.	2.5	216
122	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. British Journal of Haematology, 2011, 153, 121-128.	2.5	108
123	Exposure and safety of higher doses of recombinant factor VIIa â‰¥250â€ƒÎ¼gâ€ƒkgâ^'1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). Haemophilia, 2011, 17, 650-656.	2.1	14
124	The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. Journal of Thrombosis and Haemostasis, 2011, 9, 2229-2234.	3.8	42
125	Recognition and Management of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia in the Emergency Department. Clinical Pediatric Emergency Medicine, 2011, 12, 245-252.	0.4	0
126	Quality of life in thalassemia: A comparison of SFâ€36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal of Hematology, 2011, 86, 92-95.	4.1	63

#	Article	IF	Citations
127	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436.	4.1	63
128	Transition from pediatric to adult care for sickle cell disease: Results of a survey of pediatric providers. American Journal of Hematology, 2011, 86, 512-515.	4.1	52
129	Hormonal Contraception and Thrombotic Risk: A Multidisciplinary Approach. Pediatrics, 2011, 127, 347-357.	2.1	90
130	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. Blood, 2011, 118, 27-27.	1.4	2
131	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). Blood, 2011, 118, 340-340.	1.4	1
132	Disparities Between Two Common MRI Metrics of Liver Iron Concentration in Transfusional Siderosis. Blood, 2011, 118, 1088-1088.	1.4	0
133	Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.	1.4	0
134	Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,. Blood, 2011, 118, 3316-3316.	1.4	0
135	Liver Iron Concentration Estimates by R2* Are More Robust Than by Ferriscan During Rapid Changes in Iron Burden. Blood, 2011, 118, 5296-5296.	1.4	0
136	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
137	Intra-Patient Variability in Recombinant Activated FVII (rFVIIa) Dosing Over 3 to 8 Year Periods in Patients with Congential Hemophilia with Inhibitors Experiencing Frequent Acute Bleeding Episodes: Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry,. Blood, 2011, 118, 3314-3314.	1.4	0
138	Retrospective Review of Erythropoietin Therapy Versus Supportive Care in Newborns with Hereditary Spherocytosis (HS): Difficulties Implementing Trial Results Into Clinical Practice. Blood, 2011, 118, 2066-2066.	1.4	0
139	Corticosteroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmission. American Journal of Hematology, 2010, 85, 24-28.	4.1	53
140	Primary Care Cliniciansâ€™ Knowledge and Confidence About Newborn Screening for Sickle Cell Disease: Randomized Assessment of Educational Strategies. Journal of the National Medical Association, 2010, 102, 676-683.	0.8	9
141	Infantile Myofibroma or Lymphatic Malformation. Journal of Craniofacial Surgery, 2010, 21, 422-426.	0.7	9
142	Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Annals of Hematology, 2010, 89, 95-103.	1.8	47
143	Future research in ITP: an ICIS consensus. Annals of Hematology, 2010, 89, 19-23.	1.8	4
144	Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. Journal of Pediatrics, 2010, 157, 641-647.e2.	1.8	28

#	Article	IF	Citations
145	Pain as an emergent issue in thalassemia. American Journal of Hematology, 2010, 85, 367-370.	4.1	28
146	Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. American Journal of Hematology, 2010, 85, 802-805.	4.1	42
147	Systematic molecular genetic analysis of congenital sideroblastic anemia: Evidence for genetic heterogeneity and identification of novel mutations. Pediatric Blood and Cancer, 2010, 54, 273-278.	1.5	115
148	Education and employment status of children and adults with thalassemia in North America. Pediatric Blood and Cancer, 2010, 55, 678-683.	1.5	10
149	Oral chelation: Should it be used with young children?. Pediatric Blood and Cancer, 2010, 55, 603-605.	1.5	4
150	Preface to Cooley's Anemia: Ninth Symposium. Annals of the New York Academy of Sciences, 2010, 1202, ix-x.	3.8	2
151	Observational Cohort Study of Pediatric Inpatients With Central Venous Catheters at â€œIntermediate Riskâ€•of Thrombosis and Eligible for Anticoagulant Prophylaxis. Journal of Pediatric Oncology Nursing, 2010, 27, 325-329.	1.5	8
152	Update on Iron Chelators in Thalassemia. Hematology American Society of Hematology Education Program, 2010, 2010, 451-455.	2.5	50
153	Safety of Exposure to Recombinant Activated FVII (rFVIIa) Doses In Patients with Hemophilia and Inhibitors (CHwI) to Factors VIII or IX.. Blood, 2010, 116, 3675-3675.	1.4	1
154	Strategies to Improve Iron Chelation In Thalassemia Patients Poorly Responsive to Deferasirox:. Blood, 2010, 116, 4279-4279.	1.4	3
155	Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP). Blood, 2010, 116, 72-72.	1.4	4
156	A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. Blood, 2010, 116, 2057-2057.	1.4	0
157	Retrospective Review of 524 Cases of Pediatric ITP at An Academic Medical Center: Changes In Treatment of Childhood ITP Between 2003â€“2010. Blood, 2010, 116, 2510-2510.	1.4	0
158	Derivation of Disease-Free Induced Pluripotent Stem Cells From Patients with Pearson Marrow Pancreas Syndrome. Blood, 2010, 116, 3-3.	1.4	0
159	Changes In Health Status and Quality of Life In Adults with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study.. Blood, 2010, 116, 1533-1533.	1.4	1
160	Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.. Blood, 2010, 116, 3681-3681.	1.4	0
161	Changes In Health Status and Quality of Life In Parental Reports of Children with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study. Blood, 2010, 116, 257-257.	1.4	0
162	Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). Blood, 2010, 116, 256-256.	1.4	0

#	Article	IF	Citations
163	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	1.4	0
164	Thiamine-Responsive Megaloblastic Anemia: Identification of Novel Compound Heterozygotes and Mutation Update. Journal of Pediatrics, 2009, 155, 888-892.e1.	1.8	82
165	Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 934-941.	0.8	106
166	Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clinical Immunology, 2009, 133, 287-294.	3.2	61
167	Hemoglobin Hâ€constant spring in North America: An alpha thalassemia with frequent complications. American Journal of Hematology, 2009, 84, 759-761.	4.1	24
168	Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatric Blood and Cancer, 2009, 52, 80-84.	1.5	22
169	One year followâ€up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood and Cancer, 2009, 52, 259-262.	1.5	51
170	Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatric Blood and Cancer, 2009, 52, 865-867.	1.5	10
171	Remission from transfusionâ€dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation. Pediatric Blood and Cancer, 2009, 53, 1167-1168.	1.5	4
172	Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood, 2009, 114, 4009-4013.	1.4	75
173	Bleeding Manifestations and Management of Children with Persistent and Chronic Immune Thrombocytopenia (ITP): Data From the Intercontinental Cooperative ITP Study Group.. Blood, 2009, 114, 1315-1315.	1.4	2
174	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	1.4	3
175	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. Blood, 2009, 114, 3073-3073.	1.4	1
176	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
177	Symptoms of Anxiety and Depression Among Teens and Adults in the Thalassemia Longitudinal Cohort Study.. Blood, 2009, 114, 555-555.	1.4	20
178	Quality of Life in Adolescents and Adults with Thalassemia: A Report of the Thalassemia Longitudinal Cohort.. Blood, 2009, 114, 556-556.	1.4	0
179	The Impact of the Child with Thalassemia On the Family: Parental Assessment by Child Health Questionnaire.. Blood, 2009, 114, 1371-1371.	1.4	1
180	Renal Dysfunction in Thalassemia.. Blood, 2009, 114, 2008-2008.	1.4	1

#	Article	IF	Citations
181	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	2.2	210
182	Female monozygotic twins discordant for hemophilia A due to nonrandom Xâ€chromosome inactivation. American Journal of Hematology, 2008, 83, 778-780.	4.1	56
183	Practical implications of liver and heart iron load assessment by T2*â€MRI in children and adults with transfusionâ€dependent anemias. American Journal of Hematology, 2008, 83, 781-783.	4.1	41
184	Directâ€toâ€consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims. Journal of Thrombosis and Haemostasis, 2008, 6, 1680-1684.	3.8	12
185	Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825.	3.5	67
186	Sickle severity selectors strike out. Blood, 2008, 111, 479-479.	1.4	0
187	Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood, 2008, 112, 4003-4008.	1.4	171
188	Safety and efficacy of pegylated interferon Â-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica, 2008, 93, 1247-1251.	3.5	47
189	The Incidence and Implications of Anti-Heparin-Platelet Factor 4 Antibody Formation in a Pediatric Cardiac Surgical Population. Anesthesia and Analgesia, 2008, 107, 371-378.	2.2	37
190	Compliance with Immunizations in Splenectomized Individuals: A Study of the Splenectomized Hereditary Spherocytosis Population. Blood, 2008, 112, 1316-1316.	1.4	1
191	Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood, 2008, 112, 3890-3890.	1.4	0
192	Systematic Analysis of Known Candidate Genes in 58 Probands with Previously Uncharacterized Congenital Sideroblastic Anemia: Evidence for Genetic Heterogeneity and Identification of Novel Mutations in ALAS2 and PUS1. Blood, 2008, 112, 484-484.	1.4	0
193	Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.. Blood, 2008, 112, 1868-1868.	1.4	0
194	Nonfasting Low-Density Lipoprotein Testing: Utility for Cholesterol Screening in Pediatric Primary Care. Clinical Pediatrics, 2007, 46, 441-445.	0.8	8
195	Evaluation of the Coagulation System in Children with Two-Ventricle Congenital Heart Disease. Annals of Thoracic Surgery, 2007, 83, 1797-1803.	1.3	40
196	X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood, 2007, 109, 3297-3299.	1.4	100
197	Urinary hepcidin in congenital chronic anemias. Pediatric Blood and Cancer, 2007, 48, 57-63.	1.5	157
198	Clinical Effects and Safety of Rituximab for Treatment of Refractory Pediatric Autoimmune Diseases. Journal of Pediatrics, 2007, 150, 376-382.	1.8	64

#	Article	IF	Citations
199	Treatment with Rituximab in Benign and Malignant Hematologic Disorders in Children. Journal of Pediatrics, 2007, 150, 338-344.e1.	1.8	70
200	Validity, Reliability, and Responsiveness of a New Measure of Health-Related Quality of Life in Children with Immune Thrombocytopenic Purpura: The Kidsâ€™ ITP Tools. Journal of Pediatrics, 2007, 150, 510-515.e1.	1.8	82
201	Practical Implications of Non-Invasive MRI-Based Liver and Cardiac Iron Assessments in Children and Adults with Transfusion-Dependent Anemias.. Blood, 2007, 110, 2666-2666.	1.4	0
202	Leukocyte Apoptosis and Mitochondrial Dysfunction in Î²-Thalassemia Patients Treated with Deferasirox or Deferoxamine.. Blood, 2007, 110, 2773-2773.	1.4	0
203	Prevalence of fractures among the Thalassemia syndromes in North America. Bone, 2006, 38, 571-575.	2.9	90
204	Successful Use of Bivalirudin for Cardiac Transplantation in a Child With Heparin-induced Thrombocytopenia. Journal of Heart and Lung Transplantation, 2006, 25, 1376-1379.	0.6	55
205	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107, 2639-2642.	1.4	204
206	Screening and counseling for thalassemia. Blood, 2006, 107, 1735-1737.	1.4	9
207	Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 2006, 107, 3436-3441.	1.4	272
208	Targeted ITP strategies: Do they elucidate the biology of ITP and related disorders?. Pediatric Blood and Cancer, 2006, 47, 706-709.	1.5	6
209	Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia, 2006, 12, 218-222.	2.1	48
210	Deletion of SLC19A2, the High Affinity Thiamine Transporter, Causes Selective Inner Hair Cell Loss and an Auditory Neuropathy Phenotype. JARO - Journal of the Association for Research in Otolaryngology, 2006, 7, 211-217.	1.8	61
211	Hematology-Related Direct-to-Consumer Advertising: A Content Analysis and Verification of Claims from Print Media.. Blood, 2006, 108, 3346-3346.	1.4	0
212	Phamacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).. Blood, 2005, 106, 1243-1243.	1.4	2
213	Relationship of Transfusion and Iron-Related Complications to Cost of Care in Thalassemia.. Blood, 2005, 106, 2240-2240.	1.4	3
214	Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in Î²-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.. Blood, 2005, 106, 3598-3598.	1.4	2
215	X-Linked Gray Platelet Syndrome Due to a GATA1 Arg216Gln Mutation.. Blood, 2005, 106, 5-5.	1.4	12
216	Health-Related Quality of Life (HRQL) in Children with Severe, Chronic Immune Thrombocytopenia (cITP) Treated with Rituximab.. Blood, 2005, 106, 5575-5575.	1.4	1

#	Article	IF	Citations
217	Thiamine Deprivation Induces Reticulocytopenic Anemia in Slc19A2 Knockout Marrow: Evidence for Cell-Intrinsic Defect.. Blood, 2005, 106, 3604-3604.	1.4	0
218	High Prevalence of Fractures and Bone Pain in Thalassemia: The Thalassemia Clinical Research Network Experience.. Blood, 2005, 106, 2706-2706.	1.4	0
219	Role of Defective High-Affinity Thiamine Transporter slc19a2 in Marrow from a Mouse Model of Thiamine-Responsive Anemia Syndrome: Evidence for Defective Deoxyribose and Heme Synthesis.. Blood, 2005, 106, 516-516.	1.4	1
220	Hemoglobin Jamaica Plain â€" A Sickling Hemoglobin with Reduced Oxygen Affinity. New England Journal of Medicine, 2004, 351, 1532-1538.	27.0	30
221	Prevalence of the Metabolic Syndrome in American Adolescents. Circulation, 2004, 110, 2494-2497.	1.6	935
222	Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood, 2004, 103, 2401-2403.	1.4	60
223	Complications of Î²-thalassemia major in North America. Blood, 2004, 104, 34-39.	1.4	403
224	Myocardial iron measurements by MRI: getting to the heart of the matter. Blood, 2004, 103, 1571-1571.	1.4	0
225	Quantitative Assessment of Drug Treatment Side Effects in Children with Idiopathic Thrombocytopenic Purpura (ITP).. Blood, 2004, 104, 3030-3030.	1.4	3
226	Extracorporeal membrane oxygenation as a bridge to cardiac transplantation in a patient with cardiomyopathy and hemophilia A. Intensive Care Medicine, 2003, 29, 985-988.	8.2	11
227	Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, The, 2003, 361, 1597-1602.	13.7	301
228	Male infertility and thiamine-dependent erythroid hypoplasia in mice lacking thiamine transporter Slc19a2. Molecular Genetics and Metabolism, 2003, 80, 234-241.	1.1	22
229	Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood, 2003, 102, 3556-3561.	1.4	57
230	Time course of early induction of intracellular adhesion molecule-1 messenger RNA during reperfusion, following cardiopulmonary bypass with hypothermic circulatory arrest in lambs. Pediatric Critical Care Medicine, 2003, 4, 83-88.	0.5	0
231	Thiamine-responsive megaloblastic anemia (TRMA) syndrome: consequences of defective high-affinity thiamine transport. , 2003, , 241-248.		0
232	Genetic Ablation of the CDP/Cux Protein C Terminus Results in Hair Cycle Defects and Reduced Male Fertility. Molecular and Cellular Biology, 2002, 22, 1424-1437.	2.3	98
233	Chronic Disseminated Intravascular Coagulation and Childhood-Onset Skin Necrosis Resulting From Homozygosity for a Protein C Gla Domain Mutation, Arg15Trp. Journal of Pediatric Hematology/Oncology, 2002, 24, 685-688.	0.6	6
234	Starting out right: Kozak sequences and clots. Blood, 2002, 100, 1933-1933.	1.4	1

#	Article	IF	Citations
235	Risk factors for thromboembolism in teens: when should I test?. Current Opinion in Pediatrics, 2002, 14, 370-378.	2.0	26
236	Myocardial immediate early gene activation after cardiopulmonary bypass with cardiac ischemia-reperfusion. Annals of Thoracic Surgery, 2002, 73, 156-162.	1.3	25
237	Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 459-465.	0.8	121
238	PROSPECTIVE REEVALUATION OF THE ASSOCIATION BETWEEN THROMBOTIC DIATHESIS AND LEGG-PERTHES DISEASE. Journal of Bone and Joint Surgery - Series A, 2002, 84, 1613-1618.	3.0	62
239	Thiamine-Responsive Megaloblastic Anemia Syndrome: A Disorder of High-Affinity Thiamine Transport. Blood Cells, Molecules, and Diseases, 2001, 27, 135-138.	1.4	81
240	Characterization of a Murine High-Affinity Thiamine Transporter, Slc19a2. Molecular Genetics and Metabolism, 2001, 74, 273-280.	1.1	40
241	Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460. American Journal of Physiology - Renal Physiology, 2001, 281, G144-G150.	3.4	61
242	Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice. Blood, 2001, 98, 3658-3667.	1.4	96
243	A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome. British Journal of Haematology, 2001, 113, 508-513.	2.5	38
244	Inflammatory Bowel Disease Associated With Immune Thrombocytopenic Purpura in Children. Journal of Pediatric Gastroenterology and Nutrition, 2001, 33, 582-587.	1.8	17
245	Coagulation Abnormalities in Pediatric and Adult Patients After Sclerotherapy or Embolization of Vascular Anomalies. American Journal of Roentgenology, 2001, 177, 1359-1363.	2.2	82
246	Direct measurement of LDL-C in children: performance of two surfactant-based methods in a general pediatric population. Clinical Biochemistry, 2000, 33, 89-95.	1.9	31
247	3714 SOLITARY COLONIC ULCER ASSOCIATED WITH COAGULATION FACTOR DEFICIENCY.. Gastrointestinal Endoscopy, 2000, 51, AB134.	1.0	0
248	Transcriptional Repression of the Cystic Fibrosis Transmembrane Conductance Regulator Gene, Mediated by CCAAT Displacement Protein/cut Homolog, Is Associated with Histone Deacetylation. Journal of Biological Chemistry, 1999, 274, 7803-7815.	3.4	122
249	The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nature Genetics, 1999, 22, 305-308.	21.4	215
250	Homeoproteins CDP and SATB1 Interact: Potential for Tissue-Specific Regulation. Molecular and Cellular Biology, 1999, 19, 4918-4926.	2.3	49
251	Cux/CDP Homeoprotein Is a Component of NF-Î¼NR and Represses the Immunoglobulin Heavy Chain Intronic Enhancer by Antagonizing the Bright Transcription Activator. Molecular and Cellular Biology, 1999, 19, 284-295.	2.3	76
252	Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts. Journal of Clinical Investigation, 1999, 103, 723-729.	8.2	75

#	Article	IF	Citations
253	TIME COURSE OF EARLY ICAM-1 mRNA INDUCTION IN LUNG AND VENTRICLE FOLLOWING CARDIOPULMONARY BYPASS IN LAMBS. Critical Care Medicine, 1999, 27, 55A.	0.9	0
254	Refined mapping of the gene for thiamine-responsive megaloblastic anemia syndrome and evidence for genetic homogeneity. Human Genetics, 1998, 103, 455-461.	3.8	21
255	Prevalence of factor V Leiden in a population of patients with congenital heart disease. Canadian Journal of Anaesthesia, 1998, 45, 1176-1180.	1.6	13
256	Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. Journal of Pediatrics, 1998, 133, 275-278.	1.8	101
257	UPDATE ON GENETIC RISK FACTORS FOR THROMBOSIS AND ATHEROSCLEROTIC VASCULAR DISEASE. Hematology/Oncology Clinics of North America, 1998, 12, 1193-1209.	2.2	14
258	HEMOPHILIA. Hematology/Oncology Clinics of North America, 1998, 12, 1315-1344.	2.2	55
259	Hair Defects and Pup Loss in Mice with Targeted Deletion of the First Cut Repeat Domain of theCux/CDPHomeoprotein Gene. Developmental Biology, 1998, 200, 69-81.	2.0	44
260	Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients. JAMA Pediatrics, 1998, 152, 787-91.	3.0	10
261	Localization of the Gene for Thiamine-Responsive Megaloblastic Anemia Syndrome, on the Long Arm of Chromosome 1, by Homozygosity Mapping. American Journal of Human Genetics, 1997, 61, 1335-1341.	6.2	90
262	CASP, a novel, highly conserved alternative-splicing product of the CDP/cut/cux gene, lacks cut-repeat and homeo DNA-binding domains, and interacts with full-length CDP in vitro. Gene, 1997, 197, 73-81.	2.2	36
263	Induction of Aquaporin-1 mRNA following Cardiopulmonary Bypass and Reperfusion. Molecular Medicine, 1997, 3, 600-609.	4.4	10
264	Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1886-1895.	1.4	142
265	CCAAT Displacement Protein (CDP/cut) Recognizes a Silencer Element Within the Lactoferrin Gene Promoter. Blood, 1997, 90, 2784-2795.	1.4	56
266	Passive Cigarette Smoking and Reduced HDL Cholesterol Levels in Children With High-Risk Lipid Profiles. Circulation, 1997, 96, 1403-1407.	1.6	75
267	CCAAT Displacement Protein (CDP/cut) Recognizes a Silencer Element Within the Lactoferrin Gene Promoter. Blood, 1997, 90, 2784-2795.	1.4	6
268	Combined Schedule of Pneumococcal Conjugate Vaccine Followed by Pneumococcal Polysaccharide Vaccine in Patients With Sickle Cell Disease. â€¢ 779. Pediatric Research, 1997, 41, 132-132.	2.3	0
269	Hypoxia enhances inflammatory regulation of E-selectin through a cAMP-dependent pathway. Journal of the American College of Cardiology, 1996, 27, 411.	2.8	0
270	Blockade of selectin-mediated leukocyte adhesion improves postischemic function in lamb hearts. Annals of Thoracic Surgery, 1996, 62, 1295-1300.	1.3	37

#	Article	IF	Citations
271	Hypoxia enhances stimulus-dependent induction of E-selectin on aortic endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7075-7080.	7.1	52
272	ARMS test for diagnosis of factor VLeiden mutation, a common cause of inherited thrombotic tendency. , 1996, 10, 414-417.		8
273	CDP/cut is the DNA-binding subunit of histone gene transcription factor HiNF-D: a mechanism for gene regulation at the G1/S phase cell cycle transition point independent of transcription factor E2F.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11516-11521.	7.1	108
274	P-selectin expression in myocardium of children undergoing cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 924-933.	0.8	33
275	Severe haemophilia A in a female resulting from two de novo factor VIII mutations. British Journal of Haematology, 1995, 90, 906-909.	2.5	29
276	Repressor Activity of CCAAT Displacement Protein in HL-60 Myeloid Leukemia Cells. Journal of Biological Chemistry, 1995, 270, 12745-12750.	3.4	110
277	Induction of Interleukin-8 Messenger RNA in Heart and Skeletal Muscle During Pediatric Cardiopulmonary Bypass. Circulation, 1995, 92, 315-321.	1.6	33
278	Cardiopulmonary Bypass, Myocardial Management, and Support Techniques. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 1183-1192.	0.8	57
279	Sequence-specific DNA binding of individual cut repeats of the human CCAAT displacement/cut homeodomain protein.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7757-7761.	7.1	109
280	Inherited dyslipidemias in childhood. Current Opinion in Pediatrics, 1993, 5, 707-711.	2.0	4
281	Sequence-specific binding of HMG-I(Y) to the proximal promoter of the gp91-phox gene. Biochemical and Biophysical Research Communications, 1992, 187, 563-569.	2.1	22
282	Human CCAAT displacement protein is homologous to the Drosophila homeoprotein, cut. Nature Genetics, 1992, 1, 50-55.	21.4	216
283	Neufeld Replies. Gerontologist, The, 1991, 31, 417-417.	3.9	3
284	Uptake and subcellular distribution of [3H]arachidonic acid in murine fibrosarcoma cells measured by electron microscope autoradiography.. Journal of Cell Biology, 1985, 101, 573-581.	5.2	65
285	Preservation of arachidonoyl phospholipids during tissue processing for electron microscopic autoradiography.. Journal of Histochemistry and Cytochemistry, 1985, 33, 799-802.	2.5	11
286	Phosphoinositide turnover provides a link in stimulusâ€"response coupling. Trends in Biochemical Sciences, 1985, 10, 168-171.	7.5	190
287	Production of phosphoinositide-derived messengers. Cell, 1984, 37, 701-703.	28.9	172
288	High affinity esterification of eicosanoid precursor fatty acids by platelets.. Journal of Clinical Investigation, 1983, 72, 214-220.	8.2	86

#	Article	IF	Citations
289	Mobility, clustering, and transport of nerve growth factor in embryonal sensory cells and in a sympathetic neuronal cell line.. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77, 3469-3473.	7.1	127
290	A mutant fibroblast cell line defective in glycoprotein synthesis due to a deficiency of glucosamine phosphate acetyltransferase. Archives of Biochemistry and Biophysics, 1978, 188, 323-327.	3.0	18